Paragraph 5 Requirement to consult the appropriate committee or the Medicines Commission

Changes not yet applied. Later legislation changes this provision in ways not yet written into the text below:

sch 2 am (1.1.2010) by Medicines for Human Use (Marketing Authorisations Etc.) 2009 reg 2
Sch. 2 para. 1 words substituted by Medicines (Products for Human Use) (Amendments to Fees for Variations) 2009 reg. 9(3)
Sch. 2 para. 3 words substituted by Medicines (Marketing Authorisations and Miscellaneous Amendments) 2004 reg. 3(3)
Sch. 2 para. 2(a) substituted by Medicines (Advisory Bodies) 2005 Sch. 2 para. 1(2)
Sch. 2 para. 14(8)(a) word substituted by Medicines (Advisory Bodies) 2005 Sch. 2 para. 1(3)
Sch. 2 substituted by Medicines (Advisory Bodies) 2005 Sch. 2 para. 4
Sch. 2 para. 3 words substituted by Medicines (Codification Amendments Etc.) 2002 reg. 8(g)(i)
Sch. 2 para. 4(a) words substituted by Medicines (Codification Amendments Etc.) 2002 reg. 8(g)(ii)
Sch. 2 para. 4(b) words substituted by Medicines (Codification Amendments Etc.) 2002 reg. 8(g)(iii)

The licensing authority shall not, at any time while this Schedule applies, refuse to grant or renew the authorization applied for, or revoke, vary (other than on the application of the holder) or (subject to paragraph 13 below) suspend the relevant authorization on grounds other than those relating to the accuracy or completeness of an application, except after consultation with the appropriate committee or, if for the time being there is no such committee, the Medicines Commission.